REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 3月 2024 07:00:23 条件 Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 3月 2024 07:00:26 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 2月 2024 09:48:56 条件 NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 2月 2024 09:48:37 条件 NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 2月 2024 09:45:04 条件 NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

23 2月 2024 01:00:00 条件 Nasdaq GlobeNewswire

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

21 2月 2024 07:00:13 条件 Nasdaq GlobeNewswire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

16 2月 2024 00:59:00 条件 Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 2月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

02 2月 2024 06:30:01 条件 Nasdaq GlobeNewswire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

02 2月 2024 06:00:04 条件 Nasdaq GlobeNewswire

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

30 1月 2024 07:00:41 条件 Nasdaq GlobeNewswire

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

25 1月 2024 14:29:00 条件 Nasdaq GlobeNewswire

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

24 1月 2024 12:00:00 条件 Nasdaq GlobeNewswire

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

16 1月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

05 1月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

18 12月 2023 16:05:00 条件 Nasdaq GlobeNewswire

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

11 12月 2023 07:30:00 条件 Nasdaq GlobeNewswire

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

10 12月 2023 19:30:00 条件 Nasdaq GlobeNewswire

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

10 12月 2023 12:30:00 条件 Nasdaq GlobeNewswire